Parkinson’s disease is a chronic and progressive condition affecting the brain and nervous system. It impacts millions of ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

Oct. 30, 2024 — The amount of money people pay out-of-pocket for branded drugs to treat neurological diseases like multiple sclerosis (MS), Alzheimer's, and Parkinson's disease continues to rise, ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

About 7 million Americans live with chronic neurodegenerative diseases such as Parkinson’s disease, amyotrophic lateral ...

Vesalius Therapeutics, a company pioneering a revolutionary platform to deliver breakthrough treatments for common diseases, ...

The following column was originally published on Feb. 25, 2022. Thanks to breakthroughs in medicine and nutrition in recent years, we are living longer than ever before. But this increase in life ...

Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.

Out-of-pocket costs for drugs for neurologic diseases such as MS, Parkinson's and Alzheimer's disease ... may have long-term complications from treatment Men who undergo prostate cancer treatment ...

Some Diabetes Drugs Tied to Lower Risk of Dementia ... Researchers Target Neurogenesis in New Approach to Treat Parkinson's Disease Apr. 30, 2024 — Researchers have found a way to better ...